NIH Patents and Patent Applications

This list includes non-provisional and PCT patent filings.

Download a CSV of all Patent records.

For information on patent application codes, country codes, and patent status, see the Patents FAQ.

Tips:
Reset Search to show all records.
Sort columns by clicking on the blue column headers.
The Search function searches across all columns.
To filter results by Lead IC, Country, or Application, type or use the dropdown menu.

Lead IC Reference Number Title Country Patent Application Type Application Number Date Filed Patent Number Date Issued Patent Status Patent PDF
CC E-241-2023-0-PCT-01 GAIT ASSISTANCE SYSTEMS AND METHODS OF CONTROL THEREOF PCT PCT PCT/US2024/047743 Pending
NHLBI E-138-2023-0-PC-01 A MOLECULAR SCAFFOLD FOR DEPLETING HRPN13 AND A SELECT GROUP OF KEN BOX PROTEINS PCT PCT PCT/US2024/047709 Pending
NCATS E-042-2022-0-JP-01 SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS JP National Stage 2024-556537 Pending
NIDA E-053-2016-2-AU-09 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF AU DIV 2024219951 Pending
NCI E-019-2026-0-US-01 Identification of Inhibitors of the Catalytic RNA Subunit of RNase P US 63/696,950 Expired
NIAID E-080-2022-0-US-02 BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE US National Stage 18/848,883 Pending
NCI E-215-2024-0-US-01 COMPOUNDS FOR ACTIVATING MUCOSAL-ASSOCIATED INVARIANT T CELLS US 63/696,421 Expired
NHLBI E-218-2024-0-US-01 Cell-free chromatin immunoprecipitation to detect molecular pathways in heart
transplantation 		US 63/696,673 Abandoned
NIAID E-080-2022-0-AU-01 BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE AU National Stage 2023241824 Pending
NCATS E-042-2022-0-IN-01 SYNTHESIS OF DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS IN National Stage 202417070948 Pending
NHLBI E-087-2020-0-PC-01 HERV-E ANTIBODIES AND METHODS OF THEIR USE PCT PCT PCT/US2024/047278 Pending
NIAID E-031-2026-0-US-05 Antigenic Epstein Barr Virus Polypeptides US CON 18/887,723 Pending
NIAID E-182-2024-0-US-01 MALARIA PROTEIN NANOPARTICLE VACCINES AND USES THEREOF US 63/695,288 Expired
NCI E-098-2018-0-AU-01 T CELL RECEPTORS WHICH RECOGNIZE MUTATED EGFR AU DIV 2024219754 Pending
NIAID E-219-2023-0-PC-01 Stabilized SARS-CoV-2 S Antigens PCT PCT PCT/US2024/046623 Pending
NLM E-023-2023-0-US-02 MODIFICATION-DEPENDENT ENRICHMENT OF DNA BY GENOME OF ORIGIN US National Stage 18/847,077 Pending
NIAAA E-189-2021-0-US-02 CANNABINOID RECEPTOR MODULATING COMPOUNDS US National Stage 18/846,457 Pending
NHLBI E-127-2021-2-HK-01 COMPOSITIONS AND METHODS FOR TREATING SICKLE CELL DISEASES HK EP 62024096678.3 Pending
NCI E-075-2022-0-US-02 ANTIBODY MATERIALS AND METHODS TARGETING MICROBIAL POLYSACCHARIDES US National Stage 18/846,077 Pending
NHLBI E-035-2022-0-CN-01 PREPARATION OF ISOTOPICALLY LABELED KETOGLUTARATES AND METHODS OF HYPERPOLARIZATION THROUGH SIGNAL AMPLIFICATION BY REVERSIBLE EXCHANGE (SABRE) CN National Stage 202380026889.8 Abandoned
NIAID E-080-2022-0-IN-01 BISPECIFIC ANTIBODIES TO HIV-1 ENV AND THEIR USE IN National Stage 202417068296 Pending
NIAID E-047-2022-0-KR-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses KR National Stage 10-2024-7030215 Pending
NINDS E-113-2022-1-EP-01 RECOMBINANT POLYPEPTIDES COMPRISING SINGLE-DOMAIN ANTIBODIES TARGETING HERV-K SUBTYPE HML-2 EP National Stage 23726799.2 Pending
NIAID E-102-2022-0-PC-01 HUMAN PARAINFLUENZA VIRUS IMMUNOGENIC MOLECULES PCT PCT PCT/US2024/045542 Pending
NCI E-137-2024-0-US-01 PHOTOACTIVATABLE DYE COMPOUNDS FOR CONJUGATE FORMATION AND METHODS OF MAKING AND USING THE SAME US 63/690,585 Expired
NCI E-137-2024-1-US-01 VIRUS-LIKE PARTICLE CONJUGATES COMPRISING PHOTOACTIVATABLE DYE COMPOUNDS AND METHODS OF MAKING AND USING THE SAME US 63/690,592 Expired
NIAID E-047-2022-0-EP-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses EP National Stage 23708657.4 Pending
NCI E-101-2021-0-HK-01 T CELL RECEPTORS RECOGNIZING C135Y, R175H, OR M237I MUTATION IN P53 HK EP 62024096322.8 Pending
NIAID E-047-2022-0-ID-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses ID National Stage P00202408774 Pending
NIAID E-047-2022-0-IN-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses IN National Stage 202417065979 Pending
NCI E-046-2022-0-CN-01 T CELL THERAPY WITH VACCINATION AS A COMBINATION IMMUNOTHERAPY
AGAINST CANCER 		CN National Stage 202280092973.5 Pending
NIAID E-047-2022-0-AU-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses AU National Stage 2023219176 Pending
NIAID E-143-2025-0-US-01 COMPOSITIONS FOR OVERCOMING TETRACYCLINE ANTIBIOTIC RESISTANCE AND
METHODS OF USE THEREOF 		US 63/687,889 Expired
NHGRI E-100-2017-0-US-02 CODON-OPTIMIZED HUMAN NPC1 GENES FOR THE TREATMENT OF NIEMANN-PICK TYPE C1 DEFICIENCY AND RELATED CONDITIONS US CON 18/816,498 Pending
NHLBI E-202-2024-0-US-01 SMYD3 PROTACS FOR THE TREATMENT OF HPV-NEGATIVE SQUAMOUS CELL CARCINOMA US 63/687,489 Expired
NCI E-182-2025-0-US-01 Radiolabeled B7-H3 Antibody and Methods of Use Thereof US 63/686,437 Expired
NIAID E-001-2024-1-PC-01 Viral Strain Serology Assays PCT PCT PCT/US2024/043635 Pending
NCI E-040-2012-0-AU-01 Chimeric Antigen Receptors Targeting B-cell Maturation Antigen AU DIV 2024216293 Pending
NCATS E-218-2021-0-EP-01 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF EP National Stage 23709497.4 Pending
NIDA E-053-2016-2-US-08 DOPAMINE D3 RECEPTOR SELECTIVE ANTAGONISTS/PARTIAL AGONISTS AND USES THEREOF US CON 18/812,693 Pending
NIDCD E-220-2024-0-US-01 USING ARTIFICIAL INTELLIGENCE ALGORITHMS FOR DATA MODELING OF FUNCTIONAL HUMAN BRAIN ACTIVITY VIA FUNCTIONAL MAGNETIC RESONANCE IMAGING US 63/685,059 Expired
NCI E-028-2015-1-CN-01 Anti-Mutated Kras T Cell Receptors CN DIV 202411133523.3 Pending
CC E-140-2023-0-US-01 IMPROVEMENT OF VIRAL VECTOR MEDIATED GENE THERAPY TRANSDUCTION AND SAFETY BY TARGETING CLASS B SCAVENGER RECEPTORS US 63/684,214 Expired
NCI E-237-2017-2-CN-01 T CELL RECEPTORS RECOGNIZING MUTATED P53 CN DIV 202411117183.5 Pending
NCI E-234-2023-0-US-01 ENGINEERED RNA DEVICES IN HUMAN T-CELLS TO CONTROL GENE EXPRESSION EXTERNALLY US 63/683,318 Expired
NCI E-025-2022-0-EP-01 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF EP National Stage 23710624.0 Pending
NIAID E-047-2022-0-MX-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses MX National Stage MX/a/2024/009860 Pending
NCI E-169-2024-0-PC-01 LNA GAPMERS INHIBIT GROWTH OF CCK-BR POSITIVE CANCER PCT PCT PCT/US2024/041812 Expired
NCI E-025-2022-0-US-02 CD28 HINGE AND TRANSMEMBRANE CONTAINING CHIMERIC ANTIGEN RECEPTORS TARGETING GPC2 AND USE THEREOF US National Stage 18/837,367 Pending
NIAID E-047-2022-0-JP-01 Human Monoclonal Antibodies That Broadly Target Coronaviruses JP National Stage 2024-547536 Pending